Welcome to BrainStorm Cell Therapeutics
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm's NurOwn® Demonstrates a Statistically Significant Effect in ALS Patients
Phase 2a Results and New Analyses Presented at American Academy of Neurology
HACKENSACK, New Jersey and PETACH TIKVAH, Israel – April 21, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time today. Read More...
Click here for our Company Presentation at the Stem Cell on the Mesa meeting in San Diego, October 2013.
Click here for a summary of the data presented at the American Academy of Neurology meeting, March 2013.